Clinical Commissioning Policy: Levofloxacin nebuliser solution for chronic Pseudomonas lung infection in cystic fibrosis (adults)

Document first published:: 2 March 2018
Page updated:: 2 March 2018
Topic:: Commissioning, Specialised commissioning
Publication type:: Policy or strategy

This policy document outlines the arrangements for funding of this treatment for the population in England.

Document

Clinical Commissioning Policy: Levofloxacin nebuliser solution for chronic Pseudomonas lung infection in cystic fibrosis (adults)

Clinical Commissioning Policy: Levofloxacin nebuliser solution for chronic Pseudomonas lung infection in cystic fibrosis (adults)

16 pages